Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Vincent Bernard

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1555-608X; OpenAlex author ID A5082179566. Sources: OpenAlex.

Their work

Papers
22 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
125
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 22

  1. CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. Co-author DOI 10.1038/s44318-026-00854-5↗
  2. AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors. Co-author DOI 10.1158/2159-8290.cd-25-1119↗
  3. Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment Co-author DOI 10.64898/2026.07.10.737883↗
  4. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  5. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Co-author DOI 10.1101/2025.06.20.660757↗
  6. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  7. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  8. Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution. Co-author DOI 10.1038/s41467-022-31376-3↗
  9. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1053/j.gastro.2022.02.024↗
  10. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. First author DOI 10.1038/s41416-021-01350-9↗
  11. Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution Co-author DOI 10.1101/2021.04.13.439717↗
  12. Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples. First author DOI 10.1158/1078-0432.ccr-20-2667↗
  13. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. First author DOI 10.1158/1078-0432.ccr-20-3925↗
  14. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Co-author DOI 10.1158/2159-8290.cd-19-0297↗
  15. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Co-author DOI 10.1038/s41467-018-08109-6↗
  16. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2018.09.022↗
  17. Liquid biopsies in pancreatic cancer. First author DOI 10.1080/14737140.2019.1670063↗
  18. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progre… Co-author DOI 10.1158/1078-0432.ccr-18-1955↗
  19. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. First author DOI 10.1093/annonc/mdx542↗
  20. Dynamic changes during the treatment of pancreatic cancer. Co-author DOI 10.18632/oncotarget.24483↗
  21. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx004↗
  22. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-0831↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 18 shared papers, 2017–2026 · strength 2.01
  2. Matthew H. G. Katz · 11 shared papers, 2017–2025 · strength 1.04
  3. Paola A. Guerrero · 8 shared papers, 2019–2026 · strength 0.97
  4. Alexander Semaan · 8 shared papers, 2019–2025 · strength 0.90
  5. Jaewon James Lee · 6 shared papers, 2021–2022 · strength 0.70
  6. Maria E. Monberg · 5 shared papers, 2021–2022 · strength 0.59
  7. Jimin Min · 3 shared papers, 2025–2026 · strength 0.57
  8. Hector A. Alvarez · 8 shared papers, 2017–2021 · strength 0.54
  9. Manoop S. Bhutani · 4 shared papers, 2021–2025 · strength 0.52
  10. Cullen M. Taniguchi · 5 shared papers, 2019–2023 · strength 0.50
  11. Robert A. Wolff · 5 shared papers, 2018–2025 · strength 0.48
  12. Albert C. Koong · 2 shared papers, 2025–2026 · strength 0.45
  13. Tianyu Wang · 2 shared papers, 2025–2026 · strength 0.45
  14. Nabiollah Kamyabi · 4 shared papers, 2019–2021 · strength 0.41
  15. Thomas C. Caffrey · 2 shared papers, 2025–2026 · strength 0.40
  16. Benson Chellakkan Selvanesan · 2 shared papers, 2025–2026 · strength 0.40
  17. Michael Anthony Hollingsworth · 2 shared papers, 2025–2026 · strength 0.40
  18. Paul M. Grandgenett · 2 shared papers, 2025–2026 · strength 0.40
  19. Ching-Wei David Tzeng · 3 shared papers, 2019–2025 · strength 0.37
  20. Eugene Jon Koay · 3 shared papers, 2019–2025 · strength 0.37
  21. Guangsheng Pei · 2 shared papers, 2025 · strength 0.35
  22. Gauri Rajani Varadhachary · 5 shared papers, 2017–2021 · strength 0.35
  23. Joseph M. Herman · 3 shared papers, 2019–2023 · strength 0.32
  24. Huamin Wang · 2 shared papers, 2020–2026 · strength 0.30
  25. Ethan Bernard Ludmir · 2 shared papers, 2023–2025 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.